Founder & Principal Consultant | Salience Clinical, LLC
Clinical-Scientist Leadership for First-in-Class Therapeutics
In neuroscience, salience filters noise to spotlight what matters. At Salience Clinical, this drives our methodology, cutting through regulatory complexity to isolate clinical signals for success.
Dr. Denis Katz brings two decades advancing therapeutics in uncertain regulatory landscapes and high scientific complexity, specializing in CNS and advanced biologics where biology, biomarkers, and policy intersect.
As clinician and visual artist, Dr. Katz uncovers nuanced pathways others miss—transforming scientific breakthroughs into approved medicines.
Led global Phase III’s for regenerative cell therapies, navigating living products and first-in-class frameworks.
Integrates neurobiology, biomarkers, and precision medicine into development.
Principal strategist for BLA/NDA submissions; key regulator interface.
Architects pathways from early clinical to launch, pioneering disease-modifying approaches.
As clinician and visual artist, Dr. Katz uncovers nuanced pathways others miss—transforming scientific breakthroughs into approved medicines.
Dr. Katz earned his M.D. and M.H.A., followed by advanced postdoctoral training in neuroscience and geriatric psychiatry at Weill Medical College of Cornell University. This rare synthesis of clinical science, healthcare administration, and specialized research enables him to serve as a senior medical authority for programs navigating the most complex therapeutic landscapes.
As the Founder of Salience Clinical, LLC, he leverages this cross-functional background to bridge mechanistic science with rigorous clinical strategy—cutting through ambiguity to bring transformative therapies to market.
Empowering ideas, inspiring innovation, and creating future-ready solutions that move your vision forward—one bold step at a time.
